IDO1 and hepatocellular carcinoma: Both anti-CTLA4 and anti-PD-1 antibodies induce IDO and the combination of ICIs with 1-methyl-D-tryptophan, an inhibitor of IDO, is able to suppress tumor growth of HCC in a mouse model.